Molecular Imaging and Biology

, Volume 18, Issue 3, pp 386–392 | Cite as

Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models

  • Brandon Carney
  • Giuseppe Carlucci
  • Beatriz Salinas
  • Valentina Di Gialleonardo
  • Susanne Kossatz
  • Axel Vansteene
  • Valerie A. Longo
  • Alexander Bolaender
  • Gabriela Chiosis
  • Kayvan R. Keshari
  • Wolfgang A. Weber
  • Thomas Reiner
Research Article



The current study presents [18F]PARPi as imaging agent for PARP1 expression.


[18F]PARPi was generated by conjugating a 2H-phthalazin-1-one scaffold to 4-[18F]fluorobenzoic acid. Biochemical assays, optical in vivo competition, biodistribution analysis, positron emission tomography (PET)/X-ray computed tomography, and PET/magnetic resonance imaging studies were performed in subcutaneous and orthotopic mouse models of glioblastoma.


[18F]PARPi shows suitable pharmacokinetic properties for brain tumor imaging (IC50 = 2.8 ± 1.1 nM; logPCHI = 2.15 ± 0.41; plasma-free fraction = 63.9 ± 12.6 %) and accumulates selectively in orthotopic brain tumor tissue. Tracer accumulation in subcutaneous brain tumors was 1.82 ± 0.21 %ID/g, whereas in healthy brain, the uptake was only 0.04 ± 0.01 %ID/g.


[18F]PARPi is a selective PARP1 imaging agent that can be used to visualize glioblastoma in xenograft and orthotopic mouse models with high precision and good signal/noise ratios. It offers new opportunities to non-invasively image tumor growth and monitor interventions.

Key words

PARP1 Glioblastoma PET Orthotopic Imaging 



The authors thank Dr. Jason S. Lewis and Dr. Edmund J. Keliher for helpful discussions, Dr. Christian Brand and Christopher P. Irwin for help with experiments and Leah Bassity for editing the manuscript. Technical services provided by the MSKCC Small-Animal Imaging Core Facility, supported in part by NIH Cancer Center Support Grant No 2 P30 CA008748-48, are gratefully acknowledged. NIH Shared Instrumentation Grant No 1S10 OD016207-01, which provided funding support for the purchase of the Inveon PET/CT, is gratefully acknowledged. The authors further thank the Molecular Cytology Core at Memorial Sloan Kettering Cancer Center (P30 CA008748). The authors thank the NIH (K25EB016673 for T.R.), the Brain Tumor Center of Memorial Sloan Kettering Cancer Center (for T.R.), the Center for Molecular Imaging and Nanotechnology (for T.R.), the Clinical and Translational Science Center (CTSC) at Weill Cornell Medical College (NIH/NCATS Grant TL1TR000459 for B.C.), the American-Italian Cancer Foundation (AICF) Post-Doctoral Research Fellowship (for G.C.), the German Research Foundation (for S.K.), as well as the National Science Foundation Integrative Graduate Education and Research Traineeship (IGERT 0965983 at Hunter College) for their generous support.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors report no conflicts of interest.

Supplementary material

11307_2015_904_MOESM1_ESM.pdf (29.5 mb)
ESM 1 Supporting Information. Detailed experimental procedures, characterization data, tables, and figures provide additional documentation of the studies described in this manuscript. (PDF 30246 kb)


  1. 1.
    Rouleau M, Patel A, Hendzel MJ et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gradwohl G, Menissier de Murcia JM et al (1990) The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc Natl Acad Sci U S A 87:2990–2994CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hassa PO, Hottiger MO (2008) The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 13:3046–3082CrossRefPubMedGoogle Scholar
  4. 4.
    Yang KS, Kohler RH, Landon M et al (2015) Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci Rep 5:10129CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ossovskaya V, Koo IC, Kaldjian EP et al (2010) Upregulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1:812–821CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bièche I, De Murcia G, Lidereau R (1996) Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res 2:1163–1167PubMedGoogle Scholar
  7. 7.
    Rojo F, Garcia-Parra J, Zazo S et al (2012) Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 23:1156–1164CrossRefPubMedGoogle Scholar
  8. 8.
    Alanazi M, Pathan AA, Arifeen Z et al (2013) Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population. PLoS One 8, e85541CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Galia A, Calogero AE, Condorelli RA et al (2012) PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem EJH 56Google Scholar
  10. 10.
    Barton VN, Donson AM, Kleinschmidt-DeMasters BK et al (2009) PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer 53:1227–1230CrossRefPubMedGoogle Scholar
  11. 11.
    Staibano S, Pepe S, Lo Muzio L et al (2005) Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 36:724–731CrossRefPubMedGoogle Scholar
  12. 12.
    Thurber GM, Reiner T, Yang KS et al (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986–995CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Reiner T, Lacy J, Keliher EJ et al (2012) Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 14:169–177CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Carlucci G, Carney B, Brand C et al (2015) Dual-modality optical/PET imaging of PARP1 in glioblastoma. Mol Imaging Biol. doi: 10.1007/s11307-015-0858-0 PubMedCentralGoogle Scholar
  15. 15.
    Irwin CP, Portorreal Y, Brand C et al (2014) PARPi-FL–a fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia 16:432–440CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Keliher EJ, Klubnick JA, Reiner T et al (2014) Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes. ChemMedChem 9:1368–1373CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Keliher EJ, Reiner T, Turetsky A et al (2011) High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6:424–427CrossRefPubMedGoogle Scholar
  18. 18.
    Thurber GM, Yang KS, Reiner T et al (2013) Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 4:1504CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Reiner T, Keliher EJ, Earley S et al (2011) Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl 50:1922–1925CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zhou D, Chu W, Xu J et al (2014) Synthesis, [(1)(8)F] radiolabeling, and evaluation of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem 22:1700–1707CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Menear KA, Adcock C, Boulter R et al (2008) 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51:6581–6591CrossRefPubMedGoogle Scholar
  22. 22.
    Reiner T, Earley S, Turetsky A, Weissleder R (2010) Bioorthogonal small-molecule ligands for PARP1 imaging in living cells. Chembiochem 11:2374–2377CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Valko K, Bevan C, Reynolds D (1997) Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log P/log D. Anal Chem 69:2022–2029CrossRefPubMedGoogle Scholar
  24. 24.
    Marik J, Sutcliffe JL (2007) Fully automated preparation of n.c.a. 4-[18F]fluorobenzoic acid and N-succinimidyl 4-[18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). Appl Radiat Isot 65:199–203CrossRefPubMedGoogle Scholar
  25. 25.
    Li X, Link JM, Stekhova S et al (2008) Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem 19:1684–1688CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Chen Y, Zhang L, Hao Q (2013) Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 288:367–374CrossRefPubMedGoogle Scholar
  27. 27.
    Murai J, Huang SY, Renaud A et al (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13:433–443CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© World Molecular Imaging Society 2015

Authors and Affiliations

  • Brandon Carney
    • 1
    • 2
  • Giuseppe Carlucci
    • 1
  • Beatriz Salinas
    • 1
  • Valentina Di Gialleonardo
    • 1
  • Susanne Kossatz
    • 1
  • Axel Vansteene
    • 1
  • Valerie A. Longo
    • 3
  • Alexander Bolaender
    • 4
  • Gabriela Chiosis
    • 4
  • Kayvan R. Keshari
    • 1
    • 5
    • 6
  • Wolfgang A. Weber
    • 1
    • 5
    • 6
  • Thomas Reiner
    • 1
    • 6
  1. 1.Department of RadiologyMemorial Sloan Kettering Cancer CenterNew York CityUSA
  2. 2.Ph.D. Program in ChemistryThe Graduate Center of the City University of New YorkNew York CityUSA
  3. 3.Small-Animal Imaging Core FacilityMemorial Sloan Kettering Cancer CenterNew York CityUSA
  4. 4.Chemical Biology ProgramMemorial Sloan Kettering Cancer CenterNew York CityUSA
  5. 5.Molecular Pharmacology ProgramMemorial Sloan Kettering Cancer CenterNew York CityUSA
  6. 6.Weill Cornell Medical CollegeNew York CityUSA

Personalised recommendations